Petosemtamab (MCLA 158) is a bifunctional monoclonal antibody targeting both EGFR and LGR5 with dissociation constants (Kd) of 0.22 nM and 0.86 nM, respectively. This antibody effectively blocks EGFR signaling and induces receptor degradation specifically in LGR5-positive cancer cells. Petosemtamab is primarily utilized in research focused on solid tumors, including head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC), providing a valuable tool for investigating the pathophysiology and potential therapeutic strategies for these malignancies.
Petosemtamab (MCLA 158) is a bifunctional monoclonal antibody targeting both EGFR and LGR5 with dissociation constants (Kd) of 0.22 nM and 0.86 nM, respectively. This antibody effectively blocks EGFR signaling and induces receptor degradation specifically in LGR5-positive cancer cells. Petosemtamab is primarily utilized in research focused on solid tumors, including head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC), providing a valuable tool for investigating the pathophysiology and potential therapeutic strategies for these malignancies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
